MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...

Fixed-duration Venclexta/Gazyva or Venclexta/Imbruvica therapies show noninferior progression-free survival compared to continuous Imbruvica in untreated CLL patients. Three-year progression-free ...

In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax demonstrated a statistically ...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic ...